clinical trial · NCT06062420
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
GlaxoSmithKline·phase2·active not recruiting·n = 316
Neoplasms, Head and NeckDostarlimabBelrestotugNelistotugRemzistotug
brief summary
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).
started
Nov 14, 2023
primary completion
Sep 1, 2026
completion
Dec 31, 2027
last updated
Apr 9, 2026
official title
A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol